Changkui and his team seek to use this research program to develop improved nanomedicines for treating cancer. This will be achieved by targeting the poor delivery efficiency that currently hinders the translation of existing nanomedicines from laboratory to clinic. Successful completion will result in new nanomedicines that effectively target the tumour tissue and display superior therapeutic efficacy, and that will ultimately be developed into new treatments that improve patient outcomes.
Dr Changkui Fu